What is HC Wainwright’s Estimate for Acelyrin Q1 Earnings?

Acelyrin, Inc. (NASDAQ:SLRN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Acelyrin in a research note issued on Tuesday, January 7th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.44) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Acelyrin’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

Several other research firms have also issued reports on SLRN. Citigroup lowered their price target on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday. Wells Fargo & Company decreased their target price on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.60.

Acelyrin Trading Down 2.7 %

Acelyrin stock opened at $2.14 on Thursday. Acelyrin has a 12 month low of $1.91 and a 12 month high of $8.89. The company has a market capitalization of $214.70 million, a price-to-earnings ratio of -0.87 and a beta of 1.94. The business’s fifty day simple moving average is $4.23 and its two-hundred day simple moving average is $4.86.

Institutional Investors Weigh In On Acelyrin

Several large investors have recently bought and sold shares of the business. Franklin Resources Inc. lifted its stake in Acelyrin by 36.9% during the 3rd quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock valued at $634,000 after acquiring an additional 34,642 shares during the period. Virtu Financial LLC purchased a new position in shares of Acelyrin during the third quarter valued at approximately $50,000. Barclays PLC lifted its position in Acelyrin by 208.8% during the third quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after purchasing an additional 65,188 shares during the period. Geode Capital Management LLC boosted its holdings in Acelyrin by 30.8% in the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after purchasing an additional 388,631 shares during the last quarter. Finally, Public Employees Retirement System of Ohio grew its position in Acelyrin by 54.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 102,347 shares of the company’s stock worth $505,000 after purchasing an additional 36,154 shares during the period. 87.31% of the stock is currently owned by institutional investors.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.